| Document |
Document Title |
|
WO/2013/166121A1 |
Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; an...
|
|
WO/2013/166155A1 |
Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4)...
|
|
WO/2013/154799A1 |
The present disclosure provides tricyclic nucleosides and oligomeric compounds prepared therefrom. More particularly, the tricyclic nucleosides provided herein comprise a tricyclic ribosyl sugar moiety having a bridge between the 4' and ...
|
|
WO/2013/154798A1 |
The present disclosure provides tricyclic nucleosides and oligomeric compounds prepared therefrom. The tricyclic nucleosides each have a tricyclic ribosyl sugar moiety wherein a bridge between the 2' and 4' ribosyl ring carbon atoms furt...
|
|
WO/2013/151033A1 |
A compound or pharmaceutically acceptable salt thereof represented by general formula (I) providing a compound or pharmaceutically acceptable salt thereof having a novel structure, low adverse effects, and excellent human SGLT1 and/or SG...
|
|
WO/2013/150902A1 |
Provided is a terminal-phosphorylated oligodeoxynucleotide which is produced by introducing a deoxynucleotide containing a non-naturally-occurring nucleotide into a DNA strand and then cleaving the DNA strand through a chemical reaction ...
|
|
WO/2013/146833A1 |
The problem of the present invention is to provide a superior anti-tumor agent. A salt of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine is useful as the active ingredient of a medicine because it has at least one of character...
|
|
WO/2013/144894A1 |
The invention relates to a compound of formula (1). The invention includes all isomeric forms and tautomeric forms of the compound of formula (1) and pharmaceutically acceptable salts and derivatives such as esters and ethers. The presen...
|
|
WO/2013/142125A1 |
Disclosed herein are methods of preparing a phosphorothioate nucleotide analog, which are useful in treating diseases and/or conditions such as viral infections.
|
|
WO/2013/141350A1 |
The purpose of the present invention is to provide an oligosaccharide with high versatility that can produce a protected sulfate oligosaccharide that can become a manufacturing intermediate of polysulfated hyaluronic acid, and to provide...
|
|
WO/2013/142124A1 |
The present application relates to solid state forms, for example, crystalline forms of 2'- C-methyluridine-5 '-(O-phenyl-N-(S)- 1 -(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more s...
|
|
WO/2013/137427A1 |
Provided is a pyrimidine nucleoside compound represented by general formula (1) [wherein A1 and A2 may be the same as or different from each other and independently represent a hydrogen atom, an alkyloxycarbonyl group which may have a su...
|
|
WO/2013/135900A1 |
The present invention provides novel tricyclic nucleosides and oligomeric compounds prepared therefrom. Incorporation of one or more of the tricyclic nucleosides into an oligomeric compound is expected to enhance one or more properties o...
|
|
WO/2013/138236A1 |
Provided are compounds of Formula I, as well as pharmaceutical compositions containing compounds of Formula I and methods for treating Orthomyxoviridae virus infections by administering these compounds. The compounds, compositions, and m...
|
|
WO/2013/132489A1 |
The invention provides particular mono- and dinucleoside 5'-phosphorothioate analogues, more particularly mono- or di- adenosine or uridine 5'-di- or tri- phosphorothioate analogues in which at least one of the bridging oxygen atoms of t...
|
|
WO/2013/128393A1 |
Disclosed herein is a process for preparing highly pure Citicoline (CDP-Choline) or sodium salt of Citicoline with the aid of dicarboxylic acid or its salts. The process of the present invention results in Citicoline with a purity of mor...
|
|
WO/2013/129667A1 |
A high-purity acid-form SL containing composition which is characterized by being substantially free from acetic acid. This high-purity acid-form SL containing composition can be prepared, for example, by a process which comprises: (i) a...
|
|
WO/2013/123745A1 |
The present invention provides an azidothymidine quinoline conjugated compound N-((l-(2-(hydroxymethyl)-5-(5-methyl-2, 4-dioxo-3, 4-dihydro-pyrimidin-1(2H)-yl)-tetrahydrofuran-3-yl)-1H-1, 2, 3-triazol-4-yl) methyl)-6-(4b, 8, 8-trimethyl-...
|
|
WO/2013/122236A1 |
Provided is a protected nucleotide for elongation that makes it possible to realize a method for producing oligonucleotides by the phosphoramidite process that allows purification to be conducted by liquid-liquid extraction efficiently a...
|
|
WO/2013/121607A1 |
The present invention addresses the problem of providing a copper catalyst which has higher catalytic activity than conventional copper catalysts, is able to be easily recovered, and can be reused repeatedly. The present invention relate...
|
|
WO/2013/122112A1 |
Provided is a prodrug of a therapeutically active organic compound having: an amino group, a cyclic amino group or a hydroxyl group in the molecule; and a 2-nitro-1-imidazole propionic acid. In particular, provided is a prodrug in which ...
|
|
WO/2013/112850A1 |
The present invention provides novel anhydrous polymorph forms of 2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihy
droxytetrahydrofuran-2-yl)methyl nitrate (Compound A). The present invention also provides processes for prepa...
|
|
WO/2013/110902A1 |
The present invention relates to the use of a supramolecular system in order to remove particles from a liquid medium containing same. According to the invention, the supramolecular system includes at least one molecule having a low mole...
|
|
WO/2013/107041A1 |
A general, facile, and reversible nanocrystal (NCs) phase transfer protocol via ligand exchange using nucleotides and/or nucleosides is provided to generate reversibly water-soluble nanocrystals. This phase transfer strategy can be emplo...
|
|
WO/2013/106344A1 |
2'-C-methyl nucleosides containing a 5'-monophosphate ester (a cyclic phosphate ester of 1,3-propanediol or 2-oxo-[1,3,2]-dioxaphos-phorinane) Compositions and methods relating to 2'-C-methyl nucleosides containing a 5'-monophosphate est...
|
|
WO/2013/096680A1 |
Disclosed herein are phosphorothioate nucleotide analogs, methods of synthesizing phosphorothioate nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the...
|
|
WO/2013/092447A1 |
The present invention relates to the use of nucleoside derivatives of formula (I) wherein the symbols are as the specification, and of pharmaceutically acceptable salts thereof and to pharmaceutical compositions containing such compounds.
|
|
WO/2013/092481A1 |
The present disclosure relates to compounds of Formula (I): Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), methods of using the compounds of Formula (I) and/or compositions comprising the compounds of...
|
|
WO/2013/096679A1 |
Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are meth...
|
|
WO/2013/090550A1 |
Compounds of formula (I) as shown in the disclosure, in which X, Y, and Z are defined herein. Also disclosed are pharmaceutical compositions and therapeutical methods related to these compounds.
|
|
WO/2013/084165A1 |
The invention provides compounds of the formula:(I) which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.
|
|
WO/2013/078517A1 |
A method for isolating aragonite and organic constituents from nacre-coated shell or pearl comprising the steps: exposing the nacreous layer of nacre-coated shell or pearl to an ionic liquid; and isolating the aragonite and organic const...
|
|
WO/2013/067666A1 |
Disclosed is a method for preparing zidovudine (B). The method comprises the following steps: 1) 2'-halothymidine (A) is used as the raw material to obtain a compound of formula (I) by protecting the hydroxyl group thereof in the 5'-posi...
|
|
WO/2013/067664A1 |
The present invention relates to a method for preparing zidovudine (B). The method comprises the following steps: 1) 2'-halothymidine (A) is used as the raw material to obtain a compound of formula (I) by protecting the hydroxyl group th...
|
|
WO/2013/067669A1 |
Provided is a method for preparing zidovudine (C). The method comprises the following steps: 1) 2'-halothymidine (B) is used as the raw material to obtain a compound of formula (I) by protecting the hydroxyl group thereof in the 5'-posit...
|
|
WO/2013/061105A2 |
The invention relates to compounds of formula (I) and stereoisomers, tautomers and pharmaceutically acceptable salts thereof and processes for preparing them. In formula (I) X is -CH= or -N= or -N(R") -; Y is -N= or -N(R") -; R is an alk...
|
|
WO/2013/056046A1 |
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be admi...
|
|
WO/2013/055252A1 |
The invention relates to the field of molecular biology, virology and medicine and concerns novel biologically active compounds, more specifically salts of carbamoyl phosphonic acid esters of the general formula given in the description....
|
|
WO/2013/047567A1 |
Flavin adenine dinucleotide or a salt thereof significantly curbs the decline in viable cell count of corneal epithelial cells induced by ultraviolet radiation, and thus can act as an inhibitor of corneal epithelial cell death induced by...
|
|
WO/2013/044811A1 |
The present invention relates to the field of medical technology, and in particular relates to a kind of gemcitabine amide derivative with a novel structure. The new compounds of the present invention are very active with regard to many ...
|
|
WO/2013/040257A1 |
The present invention relates generally to 3'-OH unblocked nucleotides and nucleosides labeled and unlabeled with 5-methoxy-substituted nitrobenzyl-based photocleavable terminating groups for use in methods and systems related to DNA and...
|
|
WO/2013/039855A1 |
Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered eith...
|
|
WO/2013/036868A1 |
Synthesis and uses of conformationally restricted nucleomonomers (CRN) to prepare nucleic acid compounds. Methods for preparing nucleomonomers for nucleic acid compounds in high yields and in multi-gram scale for therapeutic modalities u...
|
|
WO/2013/036846A2 |
The present invention provides hydrophobic prodrugs of nucleic acid bases, nucleosides, and nucleotides. The compounds of the invention have a structure according to Formula I. Methods for the hypomethylation of oligonucleotides, treatme...
|
|
WO/2013/033705A2 |
A theranostic agent for inhibiting translesion DNA replication comprises natural adenine ribose analog having formula I.
|
|
WO/2013/026424A1 |
A method for the' preparation of 2-[4-[(methylamino)carbonyl]-1-H-pyrazol-1- yl]adenosine monohydrate of formula I by reaction of 2-(4-methoxycarbonylpyrazol-1-yl) adenosine of formula III with a solution of methylamine in a non-aqueous ...
|
|
WO/2013/027843A1 |
Provided is a glucoside compound that can be produced inexpensively and is capable of imparting a phosphoramidite with which a nucleic acid can be produced at a high yield and high purity. The glucoside compound is represented by chemica...
|
|
WO/2013/026142A1 |
The invention relates to the chemical synthesis of oligonucleotides, e.g., oligoribonucleotides. In another aspect, the invention relates to compounds of formula (II) processes for making these compounds, and the use thereof in the chemi...
|
|
WO/2013/023626A1 |
A method for the preparation of 2-(4-methoxycarbonylpyrazol-l-yl)adenosine of formula la and 2-(4-ethoxycarbonylpyrazol-l-yl)adenosine of formula lb by reaction of 2- hydrazinoadenosine of formula III and the sodium salt of 3,3-dimethoxy...
|
|
WO/2013/013404A1 |
The present invention relates to a water soluble derivative of camptothecin and preparation method therefor, the derivative having a structure of formula I and being appropriate in water solubility, and having anti-cancer activity and st...
|
